ALS White Paper
The Predictable Medicine Company™
Unravel Biosciences Newsletter
Unravel Biosciences kicked off the new year with a busy start. Our Predictable Medicine™ innovation stack, including BioNAV™ and Living Molecular Twins™, has begun to enable more and more advancements in drug development. In this newsletter, read updates on our RVL-001 clinical trials, our partnership with Evogene, and our newest white paper, which details how BioNAV™ addresses highly heterogeneous disorders.
RLV-001 Clinical Trials: Site Initiation
Our CEO, Richard Novak, and CMO, Neal Muni, recently visited Medellin, Colombia, to initiate our clinical trial site. The site will be used for two clinical trials: Rett syndrome and Pitt Hopkins syndrome to evaluate RVL-001 in placebo-controlled, single-blind clinical trials.
